Neuberger Berman Group
APLS

Neuberger Berman Group’s Apellis Pharmaceuticals APLS Stock Holding History

Neuberger Berman Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,675
Closed -$627K – 1900
2024
Q1 		$627K Sell
10,675
-1,783
-14% -$114K ﹤0.01% 1427
2023
Q4 		$746K Buy
+12,458
New +$632K ﹤0.01% 1366
2023
Q3 		– Sell
-4,201
Closed -$383K – 1811
2023
Q2 		$383K Sell
4,201
-36,547
-90% -$3.15M ﹤0.01% 1517
2023
Q1 		$2.69M Sell
40,748
-14,750
-27% -$851K ﹤0.01% 1008
2022
Q4 		$2.87M Buy
55,498
+11,164
+25% +$592K ﹤0.01% 988
2022
Q3 		$3.03M Buy
44,334
+290
+0.7% +$17.2K ﹤0.01% 995
2022
Q2 		$1.99M Buy
44,044
+2,138
+5% +$97.5K ﹤0.01% 1111
2022
Q1 		$2.13M Sell
41,906
-59,217
-59% -$2.61M ﹤0.01% 1161
2021
Q4 		$4.68M Buy
101,123
+36,927
+58% +$1.45M ﹤0.01% 994
2021
Q3 		$2.12M Buy
+64,196
New +$3.61M ﹤0.01% 1160

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Neuberger Berman Group's APLS Position: Q2 2024 in Review

Neuberger Berman Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 10,675 shares — an estimated $627K sold.

Neuberger Berman Group first reported a position in APLS in Q3 2021 and held it in 10 quarters. The position peaked at $4.68M in Q4 2021. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Neuberger Berman Group reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 10,675 Apellis Pharmaceuticals shares in Q2 2024, an estimated $627K.
  • Neuberger Berman Group first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Neuberger Berman Group's Apellis Pharmaceuticals position peaked at $4.68M in Q4 2021.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Neuberger Berman Group's 13F filing for Q2 2024, filed 13 Aug 2024.